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Abstract  Equid  alphaherpesvirus  3  (EHV3)  is  the  etiological  agent  of  equine  coital  exanthema
(ECE), which  is  a  venereal,  highly  contagious  disease,  characterized  by  the  formation  of  papules,
vesicles, pustules  and  ulcers  on  the  external  genitalia  of  mares  and  stallions.  EHV3  remains  in
a latent  state  after  a  successful  infection  and  there  are  latently  infected  animals  in  which  the
virus is  reactivated  and  generally  re-excreted  subclinically.  There  are  no  available  vaccines  for
this condition  and  prevention  is  based  on  the  clinical  examination  of  mares  prior  to  mating,
which allows  to  segregate  those  showing  clinical  signs.  As  this  approach  does  not  eliminate  the
risk of  contagion  in  stallions  from  subclinically  infected  mares,  there  is  a  need  for  a  speciﬁc
EHV3 treatment.  Nowadays,  there  exist  various  antiviral  compounds  of  proven  effectiveness  for
other alphaherpesviruses  affecting  humans  and  animals.  The  aim  of  the  present  study  was  to
compare  the  efﬁcacy  of  three  antiviral  compounds,  acyclovir,  ganciclovir  and  cidofovir  against
EHV3 in  vitro,  and  to  assess  their  efﬁcacy  against  six  EHV3  Argentinian  ﬁeld  isolates.  To  deter-
mine the  efﬁcacy  of  these  compounds  in  vitro,  three  parameters  were  analyzed:  reduction  of
plaque number,  reduction  of  plaque  size  and  reduction  of  viral  production.  Additionally,  the
effectiveness  of  the  three  compounds  at  an  optimum  concentration  previously  determined  in
this study  was  investigated  for  the  EHV3  ﬁeld  isolates.  Based  on  our  results,  ganciclovir  was  the
most potent  antiviral  compound  to  reduce  EHV3  replication  in  vitro  and  may  thus  be  a  valuable
candidate  for  treatment  and  prevention  of  ECE  in  mares  and  stallions.a  de  Microbiolog´ıa.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
he  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-© 2018  Asociacio´n  Argentin
open access  article  under  t
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Comparación  in  vitro  de  aciclovir,  ganciclovir  y  cidofovir  contra  alfa-herpesvirus
equino  3  y  evaluación  de  la  eﬁcacia  de  los  mismos  frente  a  6  aislamientos  de  campo
del  virus
Resumen  El  alfa-herpesvirus  equino  3  (EHV3)  es  el  agente  etiológico  del  exantema  coital
equino (ECE),  enfermedad  venérea,  altamente  contagiosa  y  caracterizada  por  la  aparición  de
pápulas, vesículas,  pústulas  y  úlceras  en  los  genitales  externos  de  yeguas  y  padrillos.  Luego
de la  primo-infección,  el  EHV3  se  mantiene  en  el  animal  en  un  estado  de  latencia  a  partir  del
cual puede  reactivar  y  excretarse,  generalmente  de  manera  subclínica.  No  existen  vacunas,
por lo  que  la  prevención  se  basa  en  la  detección  de  las  lesiones  clínicas  previo  al  servicio,  y  la
segregación de  estos  animales.  Sin  embargo,  este  abordaje  no  previene  la  infección  del  padrillo
por parte  de  yeguas  que  excretan  el  virus  de  manera  subclínica,  y  por  lo  tanto  existe  la  necesi-
dad de  un  tratamiento  especíﬁco  contra  el  EHV3.  En  la  actualidad,  existen  varios  compuestos
antivirales  de  probada  eﬁcacia  contra  herpesvirus  humanos  y  veterinarios.  El  objetivo  de  este
trabajo es  comparar  la  eﬁcacia  de  3  compuestos  antivirales,  aciclovir,  ganciclovir  y  cidofovir,
contra EHV3  in  vitro,  y  evaluar  la  eﬁcacia  de  los  mismos  contra  6  cepas  de  campo  argentinas
de EHV3.  Para  determinar  la  eﬁcacia  de  los  compuestos  in  vitro  se  evaluaron  3  parámetros:
reducción  del  número  de  placas  de  lisis,  reducción  del  taman˜o  de  placas  de  lisis  y  reducción  de
la producción  de  virus.  Adicionalmente,  la  efectividad  de  los  compuestos  en  una  concentración
óptima, previamente  determinada  en  este  estudio,  fue  determinada  para  6  cepas  de  campo
argentinas  de  EHV3.  De  acuerdo  con  los  resultados  obtenidos,  ganciclovir  fue  el  compuesto
más potente  en  reducir  la  replicación  del  EHV3  in  vitro,  y  por  lo  tanto  podría  considerarse  un
potencial candidato  para  el  tratamiento  y  la  prevención  del  ECE  en  yeguas  y  padrillos.
© 2018  Asociacio´n  Argentina  de  Microbiolog´ıa.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Introduction
Equid  alphaherpesvirus  3  (EHV3),  member  of  the  subfamily
Alphaherpesvirinae,  genus  Varicellovirus2,10 is  the  etiolog-
ical  agent  of  equine  coital  exanthema  (ECE).  ECE  is  a
highly  contagious  disease  characterized  by  the  formation
of  papules,  vesicles,  pustules  and  ulcers  on  the  external
genitalia  of  mares  and  stallions.  However,  signs  of  systemic
disease  (fever,  anorexia  and  pain)  are  rare1,4.  EHV3  infec-
tion  is  endemic  in  most  populations  of  horses  worldwide,  and
the  virus  is  primarily  transmitted  by  sexual  intercourse  but
also  by  contact  with  elements  contaminated  with  infected
secretions1,4.
As  for  the  other  alphaherpesviruses,  EHV3  remains  in  a
latent  state  after  a  successful  infection1,6.  Moreover,  spon-
taneous  reactivation  of  EHV3,  without  the  typical  clinical
manifestation,  has  been  also  demonstrated  in  mares  kept  in
isolation  for  11  months7.
Vaccines  against  EHV3  are  not  available;  thus,  preven-
tion  is  based  on  the  clinical  examination  of  mares  prior  to
the  service,  which  allows  to  segregate  those  showing  clin-
ical  signs.  However,  the  preventive  management  described
does  not  eliminate  the  possibility  of  contagion  from  latently
infected  animals  that  might  suffer  a  viral  reactivation,  which
is  generally  subclinical  and  unpredictable4.  Despite  the  self-
limiting  nature  of  EHV3  infections  and  the  fact  that  ECE
has  no  direct  effect  on  fertility  or  pregnancy,  outbreaks  of
ECE  have  a  negative  impact  on  breeding  facilities.  This  is
due  to  several  reasons:  the  need  of  temporarily  withdraw-
ing  stallions  and  mares  from  the  reproductive  activity,  the
e
h
oequirement  of  additional  treatment  for  the  affected  ani-
als,  the  extra  care  necessary  to  prevent  the  iatrogenic
pread  of  EHV3,  and  the  occurrence  of  outbreaks  of  ECE  in
rtiﬁcial  insemination  and  embryo  transfer  centers5.  To  pre-
ent  and  control  ECE,  a speciﬁc  treatment  with  an  effective
ntiviral  drug  would  be  useful.
Nowadays,  there  exist  various  antiviral  compounds
acyclic  nucleoside  analogs  and  phosphonates)  of  proven
ffectiveness  for  other  alphaherpesviruses  affecting  humans
nd  animals26.  Acyclovir,  valaciclovir  and  famciclovir  are
he  drugs  currently  approved  for  the  treatment  of  muco-
utaneous  disease  caused  by  human  alphaherpesvirus  1  and
8,18;  and  human  alphaherpesvirus  3  (Varicella-zoster  virus,
ZV).  Brivudin  is  also  another  choice  for  the  treatment  of
ZV  infections  as  it  has  demonstrated  to  be  more  potent
han  acyclovir  against  this  virus8,18. Moreover,  even  if  gan-
iclovir  and  cidofovir  have  been  proven  to  be  efﬁcacious
gainst  human  alphaherpesviruses,  their  use  is  principally
estricted  to  betaherpesvirus  infections8,18. With  regard  to
ntiviral  application  in  animals,  goats  infected  with  caprine
lphaherpesvirus  (CpHV1)  have  been  treated  topically  with
idofovir  with  promising  results21--23.  Regarding  felid  alpha-
erpesvirus  1  (FeHV1)  infection,  cidofovir  has  been  added
o  the  list  of  drugs  recommended  for  the  treatment  of  ocu-
ar  disease11,13,15,25.  In  turn,  acyclovir  is  used  both  orally
nd  topically,  in  combination  with  human  interferon  (IFN)-
,  for  the  treatment  of  ocular  FeHV113,25. With  respect  to
quid  alphaherpesvirus  1  (EHV1),  several  nucleoside  analogs
ave  been  studied  in  vitro  with  encouraging  results.  Cid-
fovir  was  found  to  be  the  most  potent  antiviral  agent  in
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educing  plaque  size  of  EHV1  when  compared  with  other
ucleoside  analogs12.  Furthermore,  ganciclovir  was  found  to
e  effective  against  EHV1  in  vitro3,12,20.
Concerning  EHV3,  there  is  limited  information  about
he  efﬁcacy  of  nucleoside  analogs  to  reduce  its  replica-
ion  in  vitro. The  effective  concentration  50%  (known  as
he  amount  of  drug  per  ml  of  medium  that  reduces  the  for-
ation  of  plaques  by  50%,  EC50)  reported  for  acyclovir  and
anciclovir  for  EHV3  plaque  number  was  4.25  g/ml9 and
.16  g/ml20,  respectively.  However,  there  is  no  informa-
ion  available  on  the  efﬁcacy  of  cidofovir  against  EHV3.  The
im  of  the  present  study  was  to  compare  the  efﬁcacy  of
hree  antiviral  compounds,  acyclovir,  ganciclovir  and  cid-
fovir  against  EHV3  in  vitro, and  to  assess  their  efﬁcacy
gainst  six  ﬁeld  isolates.
aterials and methods
rugs
cyclovir  (Cat.  No.  A4669;  ≥99%  purity  by  HPLC),  ganci-
lovir  (Cat.  No.  G2536;  ≥99%  purity  by  HPLC)  and  cidofovir
Cat.  No.  C5874;  ≥98%  purity  by  HPLC),  purchased  from
igma--Aldrich,  USA  were  used.  The  compounds  were  dis-
olved  in  Roswell  Park  Memorial  Institute  (RPMI)-1640
Cat.  No.  56510C,  Sigma  Aldrich)  medium  at  a  concen-
ration  of  1  mg/ml,  and  subsequently  ﬁltered  through
.45  and  0.22  m  ﬁlters  and  stored  at  4 ◦C  as  stock  solutions.
ell  culture
quine  dermis  (EDerm)  NBL-6  cell  line  (Cat.  No.  CCL-57,
TCC)  was  grown  and  maintained  in  complete  medium  con-
isting  of  Dulbecco  Minimum  Essential  Medium  modiﬁed
D-MEM)  supplemented  with  10%  fetal  bovine  serum  (FBS).  To
inimize  variability  between  the  experiments,  EDerm  cells
ere  used  only  on  passages  30--34,  inclusive.
iruses
he  EHV3  strain,  namely  E/9283/07  C3A,  isolated  from  ECE
esions  of  a  polo  mare  in  an  embryo  transfer  facility6, was
sed  for  the  in  vitro  comparative  assays.  To  assure  the
enetic  homogeneity  of  this  strain,  the  virus  was  cloned
y  three  plaque  puriﬁcations  in  EDerm  cells  and  replicated
our  additional  times  to  obtain  sufﬁcient  volume  for  the
ntire  study.  In  addition,  six  Argentinian  ﬁeld  isolates  of
HV3  were  selected  according  to  their  phenotypic  charac-
eristics  and  genetic  diversity  in  gG  gene  (based  on  one-base
ubstitutions  at  positions  904,  1103  and  1264)  to  compose  a
roup  of  viruses  that  best  represents  the  strains  circulat-
ng  in  Argentina.  The  six  isolates  of  EHV3  were  replicated
ndependently  in  EDerm  cells  to  obtain  sufﬁcient  volume
or  the  entire  study.  Viral  stocks  were  aliquoted  and  stored
t  −70 ◦C.  Virus  infectious  titers  were  estimated  by  the
eed  and  Muench  method19 and  expressed  both  as  the  tis-
ue  culture  infective  dose  50%  (TCID50)  per  ml  and  plaque
orming  unit  (PFU)  per  ml  (Table  1).
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omparison  of  the  efﬁcacy  of  antiviral  compounds
y plaque  number  and  plaque  size  assay
onolayers  of  EDerm  cells  seeded  in  12-wells  tissue  culture
lates  were  infected  with  500  l of  a  dilution  of  the
irus  to  obtain  up  to  30  PFU/well.  Overlay  medium  (D-MEM
upplemented  with  5%  FBS)  with  carboxymethyl  cellu-
ose  (CMC)  0.75%,  supplemented  independently  with  the
ifferent  concentrations  (0--100  g/ml)  of  each  antiviral
ompound  (acyclovir,  ganciclovir  and  cidofovir),  was  imme-
iately  added  to  four  wells  of  the  inoculated  EDerm  cells
onolayers.  For  the  comparative  analysis  of  the  six  EHV3
solates,  only  one  concentration  of  each  antiviral  was  used,
amely  acyclovir  at  5  g/ml,  ganciclovir  at  0.05  g/ml
nd  cidofovir  at  2  g/ml.  These  concentrations  have  been
hosen  based  on  the  results  obtained  previously  in  the
omparative  analysis  of  plaque  number,  plaque  size  and
iral  load  on  the  control  strain,  E/9283/07  C3A.  Cells  not
nfected  but  treated  with  each  antiviral  compound  were
sed  as  control  to  test  the  potential  cytotoxicity  of  the  com-
ounds.  After  an  incubation  period  of  72  h  at  37 ◦C  in  a  5%
O2 incubator,  the  cells  were  ﬁxed  and  stained  with  0.1%
ormalin-buffered  crystal  violet  solution12,16.  The  number
f  plaques  in  each  replicate,  at  each  concentration  of  the
hree  antiviral  compounds  and  in  untreated  control  wells,
ere  macroscopically  counted.  The  inhibitory  effect  of  the
ntiviral  compounds  on  plaque  number  was  calculated  by
he  formula  already  described12,16.
Plaque  size  was  determined  using  the  IMAGE  J
rogram  (Wright  Cell  Imaging  Facility,  Toronto  West-
rn  Research  Institute,  www.uhnresearch.ca/wcif  --
ttp://rsb.info.nih.gov/ij),  to  measure  the  pictures  of
 minimum  of  16  plaques  visualized  under  an  inverted
icroscope  with  a  magniﬁcation  of  100×. The  size  of
ach  plaque  was  expressed  as  its  area,  in  pixels  (pi).  The
nhibitory  effect  of  the  antiviral  compounds  on  plaque
ize  was  calculated  by  the  formula  already  described12,16.
he  three  compounds  were  tested  simultaneously,  in  three
ndependent  experiments.
omparison  of  the  efﬁcacy  of  antiviral  compounds
y viral  load  determination  by  quantitative  real
ime PCR  and  infectious  titer
onolayers  of  EDerm  cells  seeded  in  12-well  tissue  culture
lates  were  infected  with  500  l of  a  dilution  of  the  virus
n  order  to  obtain  up  to  30  PFU/well,  as  it  was  previously
etermined  by  a  plaque  titration  method.  For  assessing
he  antiviral  activity  against  the  E/9283/07  C3A  strain,
verlay  medium  supplemented  with  acyclovir  (5,  20  and
0  g/ml),  ganciclovir  (0.05,  0.5  and  1  g/ml)  and  cido-
ovir  (2,  20  and  40  g/ml)  was  added  after  2  h  incubation,
nd  plates  were  incubated  for  72  h,  at  37 ◦C  in  a  5%  CO2
ncubator.  For  assessing  the  antiviral  activity  against  the
ix  Argentinian  EHV3  isolates  only  one  concentration  of
ach  antiviral  was  used,  namely  acyclovir  at  5  g/ml,  ganci-
lovir  at  0.05  g/ml  and  cidofovir  at  2  g/ml.  Each  antiviral
oncentration  was  tested  in  triplicate.  Cells  infected  with
he  virus  without  antiviral  treatment  were  used  as  refe-
ence  positive  control.  To  quantify  EHV3  load  with  and
ithout  antiviral  treatment,  aliquots  of  the  supernatant
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Table  1  Control  strain  and  ﬁeld  isolates  of  EHV3  used  to  evaluate  in  vitro  efﬁcacy  of  acyclovir,  ganciclovir  and  cidofovir.
Identiﬁcation  Origin  Infective  Titer  Phenotypic
differences
Genetic
differences  at
positions
Tissue  culture
infective  dose
(TCID50)
Plaque  forming
unit  (PFU)
Plaque
sizea
Clinical
manifestation
904  1103  1264
Control  E/2983/07-3  E-Polo  horse  106 105.53 Large  Typical  ECE  C  A  G
1 E/3900/08-1  A-Thoroughbred  105.5 103.38 Small  Typical  ECE  A  C  T
2 E/3900/08-1  A-Thoroughbred  104.66 104.19 Small  Typical  ECE  A  C  T
3 E/1333/07-2  B-Thoroughbred  105.5 104.49 Large  Typical  ECE  A  C  T
4 E/976/07-154  A-Thoroughbred  105 104.80 Large  Subclinical  A  C  T
5 E/1331/07-5  C-Thoroughbred  105 104.74 Large  Typical  ECE  C  A  G
6 E/3767/08-11  D-Polo  horse  105 104.77 Large  Typical  ECE  C  A  G
Reference Cornell  University  --  --  --  Standard  --  A  A  T
a s) co
 Larg
S
T
o
c
V
d
P
T
a
t
(
t
m
S
b
c
X
ﬁ
A
I
R
C
b
T
n
r
i
e
wPlaque size (arithmetic mean of the sizes of 20 lysis plaque
(standard): Small was 1.64 times larger than the reference strain;
of  each  concentration  of  the  antiviral  compounds  were
taken  at  serial  times  post  infection:  for  strain  E/9283/07
C3A  0,  24,  48  and  72  h  and  for  the  six  ﬁeld  isolates  0,
48  and  72  h.  DNA  was  extracted  from  those  samples  by  a
commercial  kit  (High  Pure  PCR  Template  Preparation  Kit,  Cat
No.  11796828001,  ROCHE
®
),  following  the  manufacturer’s
instructions.  A  quantitative  real  time  PCR  (qPCR)  assay,
described  by  Barrandeguy  et  al.6,  which  targets  a  region  of
the  EHV3  glycoprotein  G  (gG)  gene  was  conducted.  Brieﬂy,
the  25  l  reaction  contained  12.5  l  of  TaqMan  Universal
Master  MixTM (Applied  Biosystems
®
),  5  l (1  M)  of  TaqMan
®
speciﬁc  probe  (5′-FAM-TGTGTCTCCTCATCGGCCTCATTGTCT-
TAMRA-3′)  and  1.5  l  (10  M)  of  both,  the  forward
(5′-GGGTATCGGCTTTCTCATCTTG-3′)  and  the  reverse  5mst
Real-time  PCR  System  (Applied  Biosystems
®
,  Life  Technolo-
gies,  Grand  Island,  NY).  The  cycling  program  included  2  min
at  50 ◦C,  10  min  at  95 ◦C,  followed  by  40  cycles  at  95 ◦C  for
5  s  and  60 ◦C  for  1  min.  To  assure  the  sensitivity  of  qPCR,  the
infectious  virus  titer  was  estimated  by  the  Reed  and  Muench
method19 and  expressed  as  TCID50.
Each  PCR  run  contained  two  negative  controls  and  10-fold
serially  diluted  E/9283/07  C3A  strain  to  generate  the  stan-
dard  curve.  These  dilutions  had  previously  been  quantiﬁed
in  terms  of  TCID50/ml  and  PFU/ml.  Viral  load  was  derived
from  Ct  using  the  standard  curve  generated  in  parallel  and
expressed  as  the  number  of  DNA  copies  (or  viral  equivalents)
per  volume  unit.  The  percentage  of  inhibition  was  calculated
by  the  formula  already  described  by  other  authors12,16 and
properly  adapted  to  calculate  viral  load  inhibition:
Percentage  inhibition  = 1  − (DNA  copies) antiviral
(DNA  copies) control
× 100%
For  assessing  the  antiviral  activity  against  the  E/9283/07
C3A  strain,  the  three  compounds  (each  one  at  three  con-
centrations)  were  tested  simultaneously  in  two  independent
experiments.  For  the  analysis  of  the  antiviral  activity  against
the  six  EHV3  isolates,  the  three  antivirals  (each  one  at  one
concentration)  were  tested  simultaneously  in  three  inde-
pendent  experiments.
i
b
w
nmpared with the plaque size obtained for the reference strain
e was 2.88 times larger than the reference strain.
tatistical  analysis
he  EC50 for  both  plaque  number  and  plaque  size  was
btained  by  a  non-linear  regression  ﬁt  from  a  symmetri-
al  sigmoidal  dose  (log  inhibitory)--response  curve  using  the
ariable  Slope  model,  which  ﬁtted  the  Hill  Slope  from  the
ata,  using  GraphPad  Prism  version  5.00  for  Windows,  Graph-
ad  Software,  San  Diego,  CA,  USA  (www.graphpad.com).
he  statistical  analysis  for  plaque  number  and  plaque  size
ssays  was  based  on  analysis  of  variance  (ANOVA)  using
he  MedCalc  version  12.7.0.0  for  Windows  XP/Vista/7/8
www.medcalc.org).
For  both  the  quantiﬁcation  by  qPCR  and  viral  infectious
iter,  a  non-linear  regression  ﬁt  from  a  symmetrical  sig-
oidal  dose--response  curve  was  obtained  using  the  Variable
lope  model  as  described  above.  The  statistical  analysis  was
ased  on  the  analysis  of  the  area  under  the  curve  (AUC)
alculated  using  the  MedCalc  version  12.7.0.0  for  Windows
P/Vista/7/8  (www.medcalc.org).
Regarding  the  analysis  of  the  antiviral  activity  of  the  six
eld  isolates,  for  the  three  parameters  analyzed,  a  two-way
NOVA  was  carried  out,  using  InfoStat  version  2010,  Grupo
nfoStat,  FCA,  Universidad  Nacional  de  Córdoba,  Argentina.
esults
omparison  of  the  efﬁcacy  of  antiviral  compounds
y plaque  number  and  plaque  size  assay
he  three  tested  compounds  were  able  to  reduce  plaque
umber  and  plaque  size.  Complete  inhibition  (100%)  of  EHV3
eplication  was  achieved  with  the  three  compounds  as  seen
n  the  dose--response  curves  (Fig.  1).  The  most  remarkable
ffect  on  EHV3  for  plaque  number  and  size  was  observed
ith  ganciclovir.  Cidofovir  displayed  a  lower  antiviral  activ-ty  and  acyclovir  was  the  least  effective  compound  to  reduce
oth  evaluated  parameters  (Fig.  1).  The  three  compounds
ere  more  effective  in  reducing  plaque  size  than  plaque
umber.  No  toxic  effect  on  the  EDerm  cells  was  observed
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Figure  1  Dose--response  curves  representing  the  activity  of  acyclovir,  ganciclovir  and  cidofovir  to  reduce  number  and  size  of
control strain,  E/79283/07  C3A,  induced  plaques  in  EDerm  cells.  Data  are  presented  as  the  mean  value  of  three  independent  assays
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9nd standard  deviation.  The  EC50 and  EC100 of  antiviral  compoun
ifferent superscript  letters  differ  signiﬁcantly  for  each  parame
ith  these  compounds  even  at  concentrations  as  high  as
00  g/ml.
omparison  of  the  efﬁcacy  of  antiviral  compounds
y determination  of  viral  load  by  qPCR  and
nfectious  titerll  three  compounds  completely  inhibited  (100%)  viral
eplication  at  72  h  post  infection,  at  least  with  one  of
he  concentrations  tested.  Figure  2  shows  the  viral  load
btained  at  different  concentrations  of  each  antiviral
a
a
E
cn  plaque  number  and  size  are  shown  in  each  graph.  Means  with
valuated  (one-way  ANOVA).
ompound  through  time,  both  by  qPCR  and  TCID50.  Viral
roduction  as  estimated  by  qPCR  was  inhibited  98%  at  48  h
nd  99%  at  72  h  with  acyclovir  at  20  g/ml,  ganciclovir  at
.5  g/ml  and  cidofovir  at  2  g/ml.  Lower  concentrations
f  acyclovir  (5  g/ml)  and  ganciclovir  (0.05  g/ml)  produced
7%  and  96%  inhibition,  respectively,  at  72  h  post  infection.
s  for  viral  production  estimated  by  TCID50, an  inhibition  of
8%  at  48  h was  achieved  with  ganciclovir  at  0.5  g/ml  and
n  inhibition  of  100%  was  achieved  with  acyclovir  at  5  g/ml
nd  cidofovir  at  2  g/ml.  Based  on  these  results  with  strain
/9283/07  C3A,  we  selected  one  concentration  (optimum
oncentration)  of  each  drug  to  assess  the  susceptibility  of
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Figure  2  Viral  production  by  qPCR  and  TCID50 obtained  with  three  concentrations  of  acyclovir,  ganciclovir  and  cidofovir  and
f  ED
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ﬁwithout treatment  (control)  at  different  times  post-infection  o
are presented  in  brackets.
six  different  isolates  of  EHV3.  This  concentration  (of  each
compound)  was  selected  as  the  ones  that  produced  more
than  95%  inhibition  of  viral  load  by  qPCR  in  tissue  cultures
at  72  h.  Then,  we  selected:  5  g/ml  of  acyclovir,  0.05  g/ml
of  ganciclovir  and  2  g/ml  of  cidofovir.
Susceptibility  of  ﬁeld  isolates  to  each  antiviral
compound  at  a  selected  optimum  concentration
The  susceptibility  of  EHV3  ﬁeld  isolates  to  acyclovir
(5  g/ml),  ganciclovir  (0.05  g/ml)  and  cidofovir  (2  g/ml)
r
t
h
6erm  cells  with  the  control  strain,  E/9283/07  C3A.  AUC  values
as  similar  among  the  compounds,  and  was  in  accordance
ith  the  results  obtained  for  strain  E/9283/07  C3A,  referred
hereafter  as  the  control  strain.  With  respect  to  plaque
ize,  interaction  was  shown  between  the  tested  antiviral
ompounds  and  the  different  ﬁeld  strains  (p  <  0.0048).
he  effect  of  the  three  antiviral  compounds  on  plaque  size
as  then  studied  separately  for  each  strain  (Fig.  3).  For
eld  strains  1,  2  and  5,  the  three  compounds  signiﬁcantly
educed  plaque  size  (p  <  0.05).  For  ﬁeld  strain  number  3,
here  was  a  trend  of  reduction  by  the  three  compounds;
owever,  it  was  not  signiﬁcant;  while  for  ﬁeld  strains  4,
 and  the  control  strain,  only  acyclovir  5  g/ml  showed  a
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Figure  3  Effect  of  acyclovir  at  5  g/ml  (ACV  5),  ganciclovir  at  0.05  g/ml  (GCV  0.05)  and  cidofovir  at  2  g/ml  (HPMPC  2)  on  the
size of  virus-induced  plaques  on  cells  infected  with  different  ﬁeld  strains  (n  =  6)  and  the  control  strain.  Columns  with  different
superscript  letters  differ  signiﬁcantly  (two-way  ANOVA;  Tukey  test;  p  <  0.05).
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Figure  4  Effect  of  acyclovir  5  g/ml  (ACV  5),  ganciclovir  0.05  g/ml  (GCV  0.05)  and  cidofovir  2  g/ml  (HPMPC  2)  on  the  number
of virus-induced  plaques  on  cells  infected  with  different  ﬁeld  strains  (n  =  6)  and  the  control  strain.  The  effect  of  each  compound  is
rain.
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talso shown  on  the  average  of  all  ﬁeld  strains  and  the  control  st
(two-way ANOVA;  Tukey  test;  p  <  0.05).
signiﬁcant  reduction  in  plaque  size.  When  studying  reduc-
tion  of  plaque  number  and  viral  load  determined  by  qPCR  at
48  h,  no  interaction  between  the  two  variables  (ﬁeld  strain
and  antiviral  compound)  was  observed.  However,  for  con-
sistency,  the  effects  of  the  three  antiviral  compounds  were
presented  both  separately  for  each  strain  and  in  average
for  all  the  strains  (Figs.  4  and  5).  For  plaque  number,  acy-
clovir  and  ganciclovir  were  the  most  effective  compounds,
both  of  them  producing  a  signiﬁcant  reduction  of  the  plaque
number  (Two  way  ANOVA,  p  <  0.0001).  With  regard  to  viral
load  at  48  h,  acyclovir  was  the  most  effective  compound,
followed  by  ganciclovir  and  cidofovir,  all  of  them  inducing
a  signiﬁcant  reduction  in  viral  load  for  all  ﬁeld  strains  (Two
way  ANOVA,  p  =  0.0002).  Table  2  shows  a  summary  of  the
efﬁciency  of  each  compound  against  different  ﬁeld  strains
in  vitro. Acyclovir  and  ganciclovir  showed  similar  efﬁcacy
against  EHV3  ﬁeld  strains  considering  the  3  evaluated  param-
eters.  Nevertheless,  ganciclovir  (0.05  g/ml)  was  the  most
s
w
i
t Columns  with  different  superscript  letters  differ  signiﬁcantly
otent  compound  as  it  produced  similar  results  with  a  lower
oncentration  than  acyclovir  (5  g/ml).
iscussion
n  the  present  study  the  efﬁcacy  of  acyclovir,  ganciclovir
nd  cidofovir  was  demonstrated  against  EHV3  in  vitro  by
imultaneous  comparison  of  these  three  compounds  by
laque  number,  plaque  size  and  viral  load  by  infectious
iter  and  qPCR.  The  obtained  results  extend  those  already
vailable9,20 for  acyclovir  and  ganciclovir.  In  addition,  the
tudy  reveals  that  cidofovir  is  the  least  efﬁcacious  among
he  three  tested  antivirals.  Moreover,  the  efﬁcacy  of  a
elected  optimum  concentration  of  each  antiviral  compound
as  tested  in  vitro  against  a  panel  of  six  ﬁeld  isolates,  allow-
ng  the  selection  of  ganciclovir  as  the  most  potent  antiviral
o  be  used  against  EHV3.
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Figure  5  Effect  of  acyclovir  at  5  g/ml  (ACV  5),  ganciclovir  at  0.05  g/ml  (GCV  0.05)  and  cidofovir  at  2  g/ml  (HPMPC  2)  on
the viral  titer  determined  by  qPCR  on  cells  infected  with  different  ﬁeld  strains  (n  =  6)  and  the  control  strain.  The  effect  of  each
compound is  also  shown  on  the  average  of  all  ﬁeld  strains  and  the  control  strain.  Columns  with  different  superscript  letters  differ
signiﬁcantly (two-way  ANOVA;  Tukey  test;  p  <  0.05).
Table  2  Efﬁcacy  of  antiviral  compounds  with  selected  concentrations  on  different  ﬁeld  strains  of  EHV3,  expressed  as  percentage
of inhibition.
Acyclovir  5  g/ml  Ganciclovir  0.05  g/ml  Cidofovir  2  g/ml
Reduction  of  plaque  size  84--100%  84--92%  76--85%
Reduction of  plaque  number  76--96%  58--93%  13--47%
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pReduction of  EHV3  production  48  h  post-infection  88--10
All  three  compounds  exhibited  an  effect  on  viral  replica-
ion,  demonstrated  by  the  three  investigated  parameters:
laque  number,  plaque  size  and  viral  load,  although  with
ariable  efﬁcacy.  EDerm  cells  used  in  all  assays  did  not  evi-
ence  any  change  that  could  be  associated  with  a  cytotoxic
ffect  of  the  compounds.  Indeed,  the  toxic  concentrations
n  equine  derived  cells  are  far  above  the  concentrations
ssociated  with  EHV3  antiviral  activity12.
The  EC50 to  reduce  the  plaque  number  of  ganciclovir
etermined  in  our  study  was  in  concordance  with  the  val-
es  previously  reported20;  however,  for  acyclovir,  the  value
9as  three  times  higher  than  that  found  by  Cullinane  et  al.
owever,  in  the  latter  case,  the  EHV3  strain  had  not  been
etermined  in  contrast  to  our  study,  where  the  EC50 val-
es  were  obtained  with  a  unique  strain  of  EHV3,  which  was
b
E
l
l87--100%  58--100%
haracterized  and  plaque  puriﬁed  to  ensure  homogeneity.
anciclovir  showed  the  lowest  EC50,  followed  by  cido-
ovir,  while  the  EC50 obtained  for  acyclovir  was  the  highest
ne.
For  the  compounds  evaluated  in  this  study,  the  EC50 to
educe  plaque  size  was  lower  than  the  EC50 to  reduce  plaque
umber,  as  also  observed  for  another  alphaherpesvirus,
eHV112,16.  In  contrast,  the  three  compounds  behave  differ-
ntly  between  the  two  equid  alphaherpesviruses,  EHV1  and
HV3.  For  EHV1,  the  EC50 of  acyclovir  and  ganciclovir  for
laque  size  was  almost  the  same  as  the  one  for  plaque  num-
er  although  it  was  3  times  lower  for  EHV3.  In  contrast,  for
HV1,  cidofovir  had  an  EC50 for  plaque  size  that  was  40-fold
ower  than  for  plaque  number  although  it  was  only  12-fold
ower  for  EHV312.
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2Antivirals  against  equid  alphaherpesvirus  3  
The  determination  of  viral  load  at  selected  concen-
trations  of  antiviral  compounds  showed  that  acyclovir  at
20  g/ml,  ganciclovir  at  1  g/ml  and  cidofovir  at  2  g/ml
completely  inhibit  EHV3  replication  in  vitro. In  addition  the
results  showed  that  qPCR  is  more  sensitive  than  TCID50 to
determine  the  efﬁcacy  of  antiviral  compounds  as  previously
described  for  other  alphaherpesviruses14,24.
All  investigated  EHV3  ﬁeld  strains  as  well  as  the  control
strain  exhibited  similar  susceptibility  to  selected  opti-
mum  concentrations  of  acyclovir,  ganciclovir  and  cidofovir.
With  regard  to  EHV1,  the  so-called  neuropathogenic  and
non-neuropathogenic  strains  can  be  differentiated  by  one
mutation  in  the  DNA  polymerase  gene17,27.  These  two  types
of  strains  have  comparable  susceptibility  to  acyclovir  and
ganciclovir  but  not  to  cidofovir,  which  was  found  to  be  strain-
dependent12.  Such  mutations  in  the  DNA  polymerase,  which
could  potentially  affect  the  susceptibility  of  the  enzyme  to
the  antivirals  used,  have  not  been  identiﬁed  in  EHV3.
From  our  results,  cidofovir  was  the  least  effective
compound  against  different  ﬁeld  strains  of  EHV3  related  to
the  three  investigated  parameters.  This  could  be  attributed
to  the  fact  that  the  concentration  used  for  this  assay  was
below  the  EC50 for  the  plaque  number  previously  determined
in  this  study.  However,  for  acyclovir  and  ganciclovir,  the  efﬁ-
cacy  obtained  for  the  evaluated  criteria  was  similar  at  the
selected  concentrations.  Ganciclovir  was  the  most  potent
compound  as  it  produced  similar  results  as  acyclovir  but  at
a  lower  concentration.
Conclusions
From  this  study,  it  can  be  concluded  that  ganciclovir  at
0.05  g/ml  displays  the  best  overall  inhibitory  activity
in  vitro  against  EHV3.  Considering  the  pathogenesis  of  the
infection,  especially  the  lesions  localized  in  the  genital  area,
ganciclovir  in  a  topical  formulation  should  be  considered  as
a  valuable  candidate  for  the  treatment  and  prevention  of
ECE  in  mares  and  stallions.
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